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Practice points
• Out of the 106 patients analyzed, 17% of patients had a low albumin (<3.5 g/dl) at baseline and 37.7% reported
weight loss of 5% or more in the 6 months prior to starting immunotherapy.
• Low serum albumin level status, malnutrition status based on composite nutritional status, report of at least 5%
weight loss within 6 months of presentation and baseline Eastern Cooperative Group performance status were
each significantly associated with overall survival (OS) on univariate screen (p < 0.0001, p = 0.0001, p = 0.0003 and
p = 0.0162, respectively).
• Age was also marginally associated with OS on univariate analysis (p = 0.06).
• On multivariate analysis, an interesting U-shaped relationship was noted between age and OS.
• Risk of death was highest at lower ages, insignificant at ‘middle’ ages (i.e., ages 60–75 years), and at the lowest
for elderly patients (i.e., >75 years of age).
• Patients above the estimated age of 75 years have an incrementally improved survival with every 5 year increase
in age at the time of initiation of checkpoint inhibitor, whereas the risk of death increases with every 5 year
increase in age from 45 to 60 years.
• Serum albumin less than 3.5 at baseline was associated with progression-free survival on univariate screen at
p < 0.1 level (p = 0.079).
• Overall, 96 patients (90%) experienced an adverse event, with only three patients (2.8%) experiencing a severe
event.

Background: Checkpoint inhibitors are integral to non-small-cell lung cancer treatment. Existing data
suggests that nutritional status may play a role in antitumor immunity. Materials & methods: This retrospective study of 106 non-small-cell lung cancer patients who started checkpoint inhibitors between
2014 and 2017 at our institution assessed relationship of nutritional parameters to overall survival (OS)
and progression-free survival. Results: Mean age was 68.7 ± 9.2 years and 59.4% patients were male. On
multivariate analysis for OS, hypoalbuminemia and significant weight loss were prognostic at p-values of
0.0005 and 0.0052, respectively. We noted a parabolic association between age and OS (p = 0.026, 0.0025).
Conclusion: In our study, some malnutrition parameters were associated with decreased OS. U-shape relationship between age and OS noted here warrants further evaluation.
First draft submitted: 10 March 2020; Accepted for publication: 20 March 2020; Published online:
24 April 2020
Keywords: immunotherapy • malnutrition • non-small-cell lung cancer

Lung cancer continues to be the most commonly diagnosed and deadliest form of cancer worldwide, accounting
for approximately 1.7 million deaths in 2018 alone [1]. In the USA, there was an estimated 228,150 new cases and
142,670 deaths associated with lung cancer in 2019 [2]. Checkpoint inhibitor (CPI) therapy, referred to commonly
as immunotherapy, has transformed the outcomes for advanced cancer patients over the last decade and has become
an integral component of ‘standard of care’ treatment regimens for several types of cancers, including lung cancer [3].
Currently approved CPIs inhibit CTLA4, PD-1 or PD-L1. PD-1 and PD-L1 inhibitors have shown improved
responses, progression-free survival (PFS) and overall survival (OS) in lung cancer patients compared with previous,
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‘standard of care’ chemotherapy treatments [4–12]. However, the benefit does not extend to all patients even when
enriched for extensively studied predictive markers [13]. Some patients experience no benefit at all, and some suffer
from a detrimental effect on their overall health, either due to serious immune-related adverse effects [14] or the
phenomenon of hyperprogression [15], in addition to an incremental increase on financial burden. Therefore, it is
imperative to carefully select patients who are likely to benefit for CPI immunotherapy. Significant research efforts
toward identifying optimal biomarkers that predict outcomes to CPIs are currently underway [16,17]. Two such
biomarkers that have been extensively studied and shown to have some predictive value in lung cancer, include
tumor expression of PD-L1 and tumor mutational burden [16,17]. However, both of these biomarkers are tissuebased and are imperfect in dichotomizing patients who benefit and those who do not. Many other biomarkers that
are currently being studied require tumor tissue specimens or involve cumbersome and complicated laboratorybased testing that can only be done at highly specialized centers and will likely be of limited use due to cost
constraints [18]. Hence, it would be appropriate to identify readily available clinical and laboratory parameters that
might help predict response to CPIs.
Hypothesis-generating preclinical observations suggested that baseline nutritional status may impact antitumor
immunity [19,20]. There is also clinical data showing association between malnutrition and worse outcomes from
CPI [21], and paradoxically, between obesity and improved benefit from immunotherapy [22]. Optimal assessment
of nutritional status however is still being debated [23]. In this retrospective study, we looked at predictive and
prognostic value of several factors hypothesized to be associated with nutritional status. Our study aimed to
correlate malnutrition status prior to CPI initiation, BMI serum albumin and significant weight loss at presentation
with OS and PFS.
Materials & methods
Study design

This was an institutional review board approved retrospective chart review conducted at an academic medical center.
Patients included in the study were adult advanced non-small-cell lung cancer (NSCLC) patients (≥18 years of
age) who received CPI, specifically monoclonal antibodies to PD-1 and PD-L1 as monotherapy in any line of
treatment, between January 2014 and December 2017. Patients who had received CPI previously and those with
no documented baseline albumin were excluded.
Electronic medical records were accessed to collect data on patient demographics, cancer details, details about
immunotherapy treatment, details about prior chemotherapy regimens and smoking history. In addition, we
captured data on Eastern Cooperative Group (ECOG) performance status (PS), BMI and serum albumin at the
time of presentation. We also noted if there was a significant weight loss (≥5%) reported within 6 months prior
to presentation. Information on adverse events and their grades was also collected. In addition, dates of death,
progression and last follow-up were recorded. Study data were collected and managed using Research Electronic Data
Capture (REDCap) electronic data capture tools hosted at Feinstein Institutes for Medical Research. REDCap is a
secure, web-based application designed to support data capture for research studies, providing an intuitive interface
for validated data entry, audit trails for tracking data manipulation and export procedures, automated export
procedures for seamless data downloads to common statistical packages and procedures for importing data from
external sources [24].
Statistical methods

Malnutrition status was defined as BMI <18.5 and/or serum albumin <3.5 mg/dl prior to CPI initiation. BMI
was categorized and evaluated as a binary variable (obese vs nonobese) and as a three-level categorical variable:
underweight/normal weight (BMI <25), overweight (BMI 25–30) and obese (BMI >30); due to few patients
being classified as underweight (BMI <18), these patients were combined with those of normal weight for analysis.
Serum albumin level was evaluated as a binary variable using a cutoff of <3.5 mg/dl (herein referred to as
hypoalbuminemia) versus ≥3.5 mg/dl. Significant weight loss at presentation was defined as ≥5% weight loss
within 6 months prior to presentation.
Descriptive statistics (e.g., frequencies and proportions for categorical variables and means and standard deviations
for continuous factors) were computed. OS and PFS were each analyzed by applying standard methods of survival
analysis, specifically computation of Kaplan–Meier (K-M) product limit curves [25] and performance of Cox
proportional hazards (PH) regression [26]. In K-M analyses, groups were compared using the log-rank test. The
median survival rates for each group were obtained from the K-M/Product-Limit Estimates and their corresponding
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95% CIs were computed, as appropriate. Time-to-event was measured as the number of months from initial
treatment (time from first dose of immunotherapy) to the event end point (progression or death). In cases, where
the event was not observed during the study time period, the number of months until last follow-up was used and
subject’s survival status was classified as censored at that time point. For OS, the event end point was death and for
PFS, the event was defined as either progression or death.
For all analyses, where appropriate, demographic or clinical factors that appeared to be significantly associated
with each outcome in the univariate analysis at alpha level 0.1, were considered for inclusion in a multivariable Cox
PH model. Appropriate functional form of continuous factors and PH assumption for models were assessed and
corrected as applicable. Multivariable model selection was performed using the likelihood ratio test, or backward
elimination using 5% level of significance, as appropriate, and the model with the lowest Akaike Information
Criteria (AIC) [27] was chosen when comparing non-nested models. For all analyses, a result yielding p < 0.05 was
considered statistically significant unless stated otherwise. All analyses were conducted using SAS version 9.4 (SAS
Institute Inc., NC, USA). Immune-related adverse events of all grades and serious adverse events for the entire
cohort was tabulated.
Results
A total of 115 patients were identified and 9 patients were excluded for missing baseline albumin values, leaving
106 patients included for the final analysis. Most of the patients (n = 65) had de novo Stage IV disease based
on American Joint Cancer Committee (AJCC), edition 7, while 30 patients had recurrent or progressive disease
after being previously treated for Stage III (n = 24), Stage II (n = 5) and Stage 1 (n = 2). For 10 patients, initial
staging was not recorded. The mean age was 68.7 ± 9.2 years and 63 patients (59.4%) were male. 68% of the
patients were Caucasian White, while 18, 6 and 14% were African American, Asian and unknown race, respectively.
Approximately 85% of patients had anytime history of smoking, and 21.7% were active smokers at the time of
treatment initiation. Based on previously established cutoffs for BMI [28], 8.5, 28.3, 38.7 and 24.5% were classified
as underweight, normal, overweight and obese, respectively. 17% of patients had a low albumin (<3.5 g/dl) at
baseline and 37.7% reported weight loss of 5% or more in the 6 months prior to starting immunotherapy. 23
(21.7%) of the patients were malnourished based on the composite nutritional assessment that included BMI
and baseline serum albumin level. About 17, 49, 25 and 8.7% of patients had a baseline ECOG PS of 0, 1, 2
and 3, respectively. 59 (56%) patients received nivolumab, 25 (24%) received pembrolizumab, 21 (20%) received
atezolizumab and 1 (0.9%) received avelumab. About 16, 64.1 and 14.2%, of patients received immunotherapy
in the first-, second- and third-line setting, while 5.7% of patients had received more than three lines of prior
treatment. The number of immunotherapy cycles received ranged from 1 to 36 with the median number of cycles
being 6 (interquartile range: 4–12). 47 (44.3%) patients had also received thoracic radiation previously. Table 1
provides complete descriptive statistics on the subjects included in this study.
OS

Of 106 subjects, death was observed in 43 subjects. The median OS was 16.3 months (95% CI: 10.4–22.2).
The estimated survival probability at 12 and 24 months after initiating immunotherapy were 55.2% (95% CI:
42.8–66.0) and 22.0% (95% CI: 7.4–41.4), respectively. Median OS comparisons between subsets of patients
based on various nutritional assessment parameters are depicted in Table 2.
None of the following factors: race, ethnicity, BMI, smoking status or gender, were found to be significantly
associated with OS on univariate analysis. Low serum albumin level status, malnutrition status based on composite
nutritional assessment, report of at least 5% weight loss within 6 months of presentation, and baseline ECOG
PS were each significantly associated with OS on univariate screen (p < 0.0001, p = 0.0001, p = 0.0003,
p = 0.0162, respectively). Age was also marginally associated with OS on univariate analysis (p = 0.06). Due to
the multicollinearity and correlation concerns between malnutrition status and albumin, each of these factors were
entered into separate multivariable Cox PH models, along with, ECOG score, age and initial ≥5% weight loss
status within 6 months of initiation of CPI. The final multiple Cox PH regression model included low serum
albumin level status, initial 5% weight loss and age as a quadratic term (see Figures 1 & 2, Table 3). On multivariate
analysis, an interesting U-shaped relationship was noted between age and OS (Figure 2). Risk of death was highest
at lower ages, insignificant at ‘middle’ ages (i.e., ages 60–75), and at the lowest for elderly patients (i.e., >75 years
of age). Our observations seem to suggest that patients above the estimated age of 75 years have an incrementally
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Adjusted overall survival curves for initial significant weight loss and baseline
Albumin level status
Adjusting for age, holding age at its mean (68.6 yrs)
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Figure 1.

Adjusted overall survival curves for initial significant weight loss and baseline albumin level status.
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Figure 2. Predicted overall survival curves for various patient age profiles, holding serum albumin ≥3.5 g/dl and
reported ≥5% weight loss within 6 months prior to immunotherapy initiation.
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Table 1. Patient demographics and characteristics.
Baseline characteristic

Total (n = 106)

Age (years)

68.6 ± 9.2

Male

63 (59.4%)

Female

43 (41.6%)

Race:
– White
– Black
– Asian
– Unknown

68 (64.2%)
18 (17.0%)
6 (5.7%)
14 (13.2%)

BMI

25.7 ± 5.4

Smoking status:
– Yes
– Former

23 (21.7%)
67 (63.2%)

Baseline albumin

3.9 ± 0.4

Baseline albumin (⬍3.5 g/dl)

18 (17%)

Malnourished based CNA

23 (21.7%)

Initial ≥5% weight loss upon starting immunotherapy

40 (37.7%)

ECOG PS:
–0
–1
–2
–3

18 (17.3%)
51 (49.0%)
26 (25.0%)
9 (8.7%)

Line of therapy
– First
– Second
– Third or more

17 (16.0%)
68 (64.2%)
21 (19.8%)

Morphological classification
– Adenocarcinoma
– Squamous
– Small cell

68 (67.3%)
25 (24.8%)
8 (7.9%)

Radiation during immunotherapy

10 (9.4%)

Number of cycles, median (IQR)

4 (6–12)

Data represented as n (%) or mean (± SD) unless otherwise stated.
CNA: Composite nutritional assessment; ECOG PS: Eastern Cooperative Group performance status; IQR: Interquartile range; SD: Standard deviation.

Table 2. Univariate comparisons between outcomes of patients based on various nutritional parameters.
Variables

N

Median OS, months (95% CI)

p-value

0.0001

Median PFS, months (95% CI)

p-value

6.3 (4.1–9.9)

0.25

Composite nutritional status
Malnutrition status

23

7.1 (4.8–10.4)

Normal nutritional status

83

21.7 (11.9 to not estimable)

Underweight/Normal BMI

50

7.3 (5.6–15.9)

Overweight

30

8.5 (3.5 to not estimable)

Not estimable

Obese

26

11.9 (6.9–17.6)

9.4 (4.1–17.3)

Weight loss ⬎5%

40

6.1 (4.0–17.6)

No weight loss ⬎5%

66

21.7 (11.9 to not estimable)

⬍3.5 g/dl

18

6.9 (2–10.4)

≥3.5 g/dl

88

19.5 (11.9–23.3)

8.5 (5.6–16.5)

BMI
0.4

19.5 (9.6–23.3)

0.98

Weight loss
0.0003

7.4 (4.6–15.9)

0.75

8.5 (5.6–16.5)

Albumin
0.00001

5.2 (3.9–9.4)

0.0792

8.5 (5.6–15.9)

OS: Overall survival; PFS: Progression-free survival.

improved survival with every 5-year increase in age at the time of initiation of CPI, whereas the risk of death
increases with every 5-year increase in age from 45 to 60 years.
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Table 3. Final cox proportional hazard model for mortality.
Parameter

Parameter
Estimate

Standard Error

p-value

Hazard Ratio

Was there initial (⬎5%) weight loss upon starting
immunotherapy?
Yes vs No

0.91

0.32

0.0052

2.48

1.31

4.68

Albumin ⬍3.5 g/dl

1.37

0.39

0.0005

3.95

1.83

8.54

Age when started immunotherapy

0.81

0.36

0.026

–

–

–

Age†

-0.01

0.00

0.0249

–

–

–

† Hazard

95% CI

ratios for age are not estimated within this table, but refer to the Figure 2 for visualization of the quadratic relationship.

PFS

Among 106 subjects, progression events were observed in 50 subjects, with five deaths occurring before progression
could be observed, with the remaining 51 subjects’ observations censored. The median time of PFS was 7.4 months
(95% CI: 5.6–12.1). The estimated PFS probability at 12 months after initiating immunotherapy was 39.7% (95%
CI: 27.9–51.3). The estimated PFS probability at 18 months after initiating immunotherapy was 17.3% (95% CI:
11.5–39.3).
None of the following factors were found to have significant association with PFS: race, ethnicity, BMI, obesity,
smoking status, gender, ECOG PS, malnutrition status, presence of at least 5% initial weight loss at presentation
or age (p = 0.7, p = 0.27, p = 0.98, p = 0.96, p = 0.88, p = 0.87, p = 0.77, p = 0.25, p = 0.74 and p = 0.76,
respectively). Serum albumin less than 3.5 at baseline was associated with PFS on univariate screen at p < 0.1
level (p = 0.079). Given that no factor was significantly associated with PFS other than low albumin status from
univariate screen, a multivariable Cox PH model was not built.
Adverse events

Overall, 96 patients (90%) experienced an adverse event, with only three patients (2.8%) experiencing a severe event.
Fatigue/weakness (54.7%), dyspnea (21.7%), rash/pruritus (16%), diarrhea/colitis (15.1%) and nausea/vomiting
(13.2%) were the most common adverse events. A total of 20 patients (21.7%) discontinued CPI due to adverse
events and 5 patients (4.7%) required hospital admission. The incidence of adverse events of all grades and severe
adverse events are depicted in Table 4.
Discussion
The relationship between nutritional status and homeostasis of the immune system and anticancer immunity is a
complex one and recent research into this field is shedding some light into this very intriguing association [19,20,29–32].
Advanced cancer is associated with a cancer-induced wasting syndrome, also called cancer cachexia, which results
in caloric deficiency [33]. Caloric deficiency, in turn is linked to immunosuppression, increased susceptibility to
infection and has been shown to be associated with cancer progression but somewhat protective against autoimmune
diseases [19,31]. Obesity on the other hand is associated with an overactive immune system, auto-immunity and
enhanced anticancer immunity [32,34,35]. Nutritional status has influence on T-cell metabolism and function
through mediation by several inter-related cytokines such as IL-6 and TNF-α as well as stress hormones [19]. In
mice models, both TNF-α and IL-6 were noted to be markedly elevated in precachexic and cachexic states of
cancer patients [19,36]. One of the many possible mechanisms by which IL-6 interplays with tumor immunity is
its involvement in decreasing hepatic ketogenic potential through suppression of PPARalpha [19]. Hypoketonemia
which can be considered a systemic metabolic stress response resulting from precachectic and cachectic states in turn
triggers a marked elevation in glucocorticoid levels, which has been in turn been shown to be associated with poor
response to immunotherapy and overall poor outcomes [19]. Contrariwise, obesity has shown to be associated with
improved responses to CPI in multiple recent studies [20,22,34,37,38]. The mechanistic explanation for this association
is currently being elucidated but there are some hypotheses. Macrophages are the most abundant immune cells in
adipose tissues and during periods of weight gain, there is an influx of inflammatory macrophages into the adipose
tissue and this leads release of cytokines such as TNF-α [20,39]. Thus, obesity results in heightened inflammatory
response that interferes with immune modulation, inhibits antitumor immunity and results in immune exhaustion.
CPI therapy seems to reverse this process and enhance antitumor immunity.
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Table 4. Adverse events for the entire subject cohort.
Adverse events

Total (n = 106)
All grades

Grade 3/4

Total

96 (90.6%)

3 (2.8%)

Fatigue/weakness

58 (54.7%)

1 (0.9%)

Diarrhea/colitis

16 (15.1%)

0 (0%)

Hypophysitis

0 (0%)

0 (0%)

Thyroid

11 (10.4%)

0 (0%)

Adrenal insufficiency

1 (0.9%)

0 (0%)

Pneumonitis

6 (5.7%)

2 (1.8%)

Rash/pruritis

17 (16.0%)

0 (0%)

Liver

2 (1.8%)

0 (0%)

Nephropathy

9 (8.5%)

0 (0%)

Dyspnea

23 (21.7%)

0 (0%)

Edema

11 (10.4%)

0 (0%)

Constipation

9 (8.5%)

0 (0%)

Nausea/vomiting

14 (13.2%)

0 (0%)

A fib

1 (0.9%)

0 (0%)

Arthralgia/myalgia

10 (9.4%)

0 (0%)

Pneumonia/upper respiratory infection

12 (11.3%)

0 (0%)

Flu like symptoms

2 (1.8%)

0 (0%)

Hypersensitivity reaction

1 (0.9%)

0 (0%)

Other

10 (9.4%)

0 (0%)

Discontinued due to adverse event

20 (18.9%)

While there is a now general agreement that nutritional status is an important factor in predicting responses
to CPI, there has been considerable variability when it comes to methods used for assessment of nutritional
status [23]. Common tools include subjective quantification of weight loss by patients [40]; objective anthropometric
measurements such as BMI [41,42]; skinfold thickness [43] and laboratory assessments such as serum CRP [44],
and pre-treatment serum albumin [44,45] and dietary assessments such as 24-h food intake recall [46]; and body
composition assessment such as lean muscle mass area calculated from axial-view computerized tomographic
images of the abdomen at the level of L3 spine [47]. Combining various parameters is sometimes utilized for
nutritional assessment and one of such composite measure is integration of BMI and serum albumin which has
been validated in patients on hemodialysis and cancer [48]. In our study, we utilized nutritional parameters that were
readily available from a retrospective chart review. We chose weight loss of 5% or more in the 6 months preceding
CPI therapy, BMI, obesity, composite assessment of malnutrition using BMI and serum albumin as our primary
measures of nutritional status.
Velocity of weight loss has been historically used as a measure for malnutrition and the velocity of weight loss
has been shown to correspond with other cancer related symptoms such as anorexia and fatigue as well as disease
outcomes [40]. Weight loss by itself as a measure of nutrition is flawed since this is in many cases, this is subjective
and dependent on patients’ recall. It does not discriminate between intentional and unintentional weight loss. In
our study, there was a significant association between having a significant unintentional weight loss (5% or more
in 6 months) and decreased OS probability.
BMI has been shown to be predictive of outcomes in several disease conditions such as Type 2 diabetes [49].
It has associated with increased risk for developing certain cancers such as that of colon and endometrium [34].
Despite this, using BMI as a sole measure of nutritional status has several pitfalls: BMI cannot distinguish fat and
lean masses, and it may be particularly in cancer patients may have a relative increase in body fat and fluids, and
a severe decline in lean tissue [50]. In our study, BMI was not associated with OS or PFS. We did not observe
improved outcomes associated with overweight and obese status in our patient population. While this might have
simply been a reflection of the small size of our study population, it may also support previous reports of BMI as
an inaccurate measure of nutritional status.
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Albumin is a protein synthesized in the liver and has a half-life of 14–20 days, making serum albumin an easy,
stable measure for nutritional status [45]. However, albumin levels are easily affected by its levels are affected by
inflammation, liver dysfunction and many other conditions in addition to nutritional status. In our study, we
found that the serum albumin less than 3.5 was the only factor that was possibly associated with worse OS and
PFS probabilities.
Theoretically, combining with BMI and albumin might be a more efficient tool to assess nutrition because they
are likely to complement each other. For example, in patients with falsely elevated BMI because of increased fluids
either from third-spacing or effusions, low serum albumin may point toward malnutrition. This composite measure
has been validated in prior studies [43]. In our study, we used albumin cutoff of less than 3.5 and/or BMI <18.5
as a marker of malnutrition status. This composite score was significantly associated with OS in univariate screen.
However, this measure was not incorporated into the final Cox-proportionate multivariable model selection, due
to multicollinearity and correlation concerns if both malnutrition status and albumin were to be included. The
model with low serum albumin status was chosen as having the best model fit.
An interesting and unexpected quadratic relationship between age and survival was observed in our study. This
suggests that for our cohort, younger age is associated with greatest hazard of death at earlier time points, which
declines with increasing age. In the middle age range of the cohort, the effect of age on survival is not meaningful.
However, as age at start of therapy continues at about 75 years or older, the effect of age on survival seems to improve
(risk of death decreases). To better understand the clinical background and biologic rationale of the relationship
between age and clinical outcomes to CPI, we reviewed relevant literature on the use of immunotherapy in elderly
patients with cancer.
Counterintuitive to expectations that CPI would be ineffective in elderly patients with cancer due to immunesenescence, which is an age-related decline in the immune function [51], recent studies have shown that age is not
an adverse predictive factor for responses to CPI and may in fact be a favorable predictive factor for patients on
CPI. In a retrospective cohort study of 500 patients with metastatic melanoma treated with PD1 inhibitors as
monotherapy, 144 patients who were ≥65 years age were selected for further analysis. They were then stratified into
two age groups of 65–79 years and 80–100 years. Complete response rates were significantly higher for the older
cohort of patient (48 vs 20%; p = 0.001) and overall response also trended higher as compared with the younger
patients [52]. Safety analysis showed similar profiles of immune-related adverse events, and similar rates of grade 3
and 4 toxicity.
Another retrospective analysis of 246 patients focused solely on a population of patients with NSCLC who
received PD-L1 inhibitors [53]. Patients in this study were divided into age groups of <60, 60–69, 70–79 and
≥80 years. The findings of this study differed a little from the aforementioned study in that patients <60 years had
a less favorable survival outcome. With increasing age, outcomes improved and then worsened again after age 80.
One possible explanation for the somewhat contrasting finding between these studies is the inherent differences
between the patient populations in the two studies. It is possible, that elderly patients with lung cancer age have
higher prevalence of co-morbid conditions [54], such as heart and lung diseases which become a source of competing
mortality. Also, the age range in the former study contained very elderly individuals, well past 80 years of age.
Additional methodological issues with these studies including selection bias and unmeasured confounders, might
have contributed to the minor differences between the study results. A meta-analysis of nine randomized controlled
clinical trials was performed on a total of 5265 patients who received CPIs for various indications, including lung
cancer, melanoma and renal cancer [55]. Patients were divided into younger and older groups with an age cutoff
for subgroup analysis of 65–70 years, CPI improved OS in both the younger (HR: 0.75; 95% CI: 0.68–0.82) and
older (HR: 0.73; 95% CI: 0.62–0.87) groups. Since this meta-analysis included mostly melanoma randomized
controlled trials, its generalizability to lung cancer is limited. Nevertheless, all these studies support activity and
safety of CPI in the elderly patient population and our study echoed the same finding by demonstrating an
interesting U-shape relationship between age and CPI outcomes. A plausible explanation for this rather paradoxical
observation was explored in preclinical studies. In a melanoma mouse model [56], response to PD1 inhibition was
significantly worse for younger (2 months) mice compared with older (10 months) ones. The study suggested that
one explanation for this observation may be because of increase in immunosuppressive FOXP3+ Tregs within the
tumor microenvironment and decrease in CD8+ T effector cells, which serve as the target of PDL1 inhibition in
the younger mice.
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Limitations

There are several limitations to our study. First, this study was retrospective in nature. Furthermore, due to the
limited sample size, it is possible that there was insufficient power to detect small, yet clinically meaningful
differences in PFS probabilities for other risk factors. Third, as previously mentioned some of the limitations of
using BMI as a sole measure of nutritional status, it was felt that albumin would be a good complement to assess
nutritional status.
Conclusion
Our study indicates that pretreatment nutritional status is associated with OS and possibly with PFS as well
for patients treated with CPI therapy. Optimal measure for nutritional status is unclear but based on our single
institution retrospective review, serum albumin and significant weight loss prior to starting CPI were significantly
associated with OS in multivariate analysis. We noted an interesting parabolic age-response correlation for patients
with NSCLC treated with CPI, and this warrants further evaluation with a larger sample size and preferably in a
prospective fashion.
Future perspective
Immunotherapy has changed the way we treat cancer and for some, long, durable responses have been shown.
However, this benefit does not extend to all patients, with some patients experiencing no benefit at all and some
suffering from a detrimental effect on their overall health either due to serious immune-related adverse effects. It is
essential to carefully select patients who are likely to benefit for CPI immunotherapy. Significant research efforts
toward identifying optimal biomarkers that predict outcomes to CPIs are currently underway. Nutritional status
may play a role in antitumor immunity, but is still being debated. Further research will provide additional, much
needed insight on this topic.
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